TY - JOUR

T1 - Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma

T2 - An international multicentre analysis

AU - May, Taymaa

AU - Bernardini, Marcus

AU - Lheureux, Stephanie

AU - Aben, Katja K.H.

AU - Bandera, Elisa V.

AU - Beckmann, Matthias W.

AU - Benitez, Javier

AU - Berchuck, Andrew

AU - Bjørge, Line

AU - Carney, Michael E.

AU - Cramer, Daniel W.

AU - Defazio, Anna

AU - Dörk, Thilo

AU - Eccles, Diana M.

AU - Friedlander, Michael

AU - García, María Jose

AU - Goode, Ellen L.

AU - Hein, Alexander

AU - Jensen, Allan

AU - Johnatty, Sharon

AU - Kennedy, Catherine J.

AU - Kiemeney, Lambertus A.

AU - Kjær, Susanne K.

AU - Kupryjanczyk, Jolanta

AU - Matsuo, Keitaro

AU - McGuire, Valerie

AU - Modugno, Francesmary

AU - Paddock, Lisa E.

AU - Pejovic, Tanja

AU - Phelan, Catherine M.

AU - Riggan, Marjorie J.

AU - Rodriguez-Antona, Cristina

AU - Rothstein, Joseph H.

AU - Sieh, Weiva

AU - Song, Honglin

AU - Terry, Kathryn L.

AU - Altena, Anne M.Van

AU - Vanderstichele, Adriaan

AU - Vergote, Ignace

AU - Thomsen, Liv Cecilie Vestrheim

AU - Webb, Penelope M.

AU - Wentzensen, Nicolas

AU - Wilkens, Lynne R.

AU - Ziogas, Argyrios

AU - Jiang, Haiyan

AU - Tone, Alicia

AU - Ovarian Cancer Association Consortium

AU - Australian Ovarian Cancer Study Group

N1 - Publisher Copyright: © 2023 Canadian Medical Association. All rights reserved.

PY - 2023

Y1 - 2023

N2 - Background: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC. Methods: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves. Results: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage. Conclusion: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.

AB - Background: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC. Methods: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves. Results: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage. Conclusion: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.

U2 - 10.1503/cjs.017020

DO - 10.1503/cjs.017020

M3 - Journal article

C2 - 37369443

AN - SCOPUS:85166274935

VL - 66

SP - E310-E320

JO - C M A J

JF - C M A J

SN - 0008-4409

IS - 3

ER -